November 2, 2021
(Reuters) – Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.
The company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)
Source: One America News Network
